CDKN2A and neoplasm: Patients with a p16+/HPV16- OPSCC have a significantly worse prognosis compared to p16+/HPV+ tumours [49], [96], [97], [98], [99], [100] and show a slightly better risk profile than HPV-/p16– tumours [49], [101].